Clinical trials
- Home
- CLINICAL TRIALS
- Ongoing Clinical Trials
- Now Enrolling : Phase 2 Clinical Trial for EI-001 (Indemakitug Anti-IFN gamma antibody ) for Non-Segmental Vitiligo (NSV)
Now Enrolling : Phase 2 Clinical Trial for EI-001 (Indemakitug Anti-IFN gamma antibody ) for Non-Segmental Vitiligo (NSV)
October 07,2026
Now Recruiting Participants with Non-Segmental Vitiligo (NSV)
Our institution is conducting a Phase 2, randomized, double-blind, placebo-controlled clinical trial to evaluate whether the investigational drug EI-001 (Indemakitug - Human Anti-IFN-gamma monoclonal antibody) may help improve the symptoms of non-segmental vitiligo.
1. Who Can Participate?
You may be eligible if you:
2. What Does the Study Involve?
3. Potential Benefits and Risks
Possible Benefits
Possible side effects may include:
Principal Investigator
Chau Yee Ng, MD PhD
Pigment Specialist, Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan
Associate Professor, College of Medicine, Chang Gung University
Recruitment Now Open
For more information, please contact:
Study Coordinators: Min-Yi Chou, RN / Man-Ting Lin, RN
Phone: +886 922-216-828 / +886 928-577-665
Our institution is conducting a Phase 2, randomized, double-blind, placebo-controlled clinical trial to evaluate whether the investigational drug EI-001 (Indemakitug - Human Anti-IFN-gamma monoclonal antibody) may help improve the symptoms of non-segmental vitiligo.
1. Who Can Participate?
You may be eligible if you:
- Are between 18 and 65 years of age
- Have been diagnosed with non-segmental vitiligo (NSV) by a physician
- Have had vitiligo for at least 3 months
- Have received previous vitiligo treatment with insufficient response, or are unable to use standard therapies
2. What Does the Study Involve?
- Study duration: approximately 42 weeks
- Treatment period: the investigational drug will be administered once every 2 weeks for a total of 12 infusions
- Route of administration: intravenous (IV) infusion
- Study procedures may include:
- Physical examinations
- Blood and urine tests
- Electrocardiogram (ECG)
- Chest X-ray
- Vitiligo photography and assessments
3. Potential Benefits and Risks
Possible Benefits
- Opportunity to receive an investigational treatment for vitiligo (benefit cannot be guaranteed)
- Regular health monitoring and vitiligo assessments throughout the study
Possible side effects may include:
- Immune-related or allergic reactions (such as fever, rash, or nausea)
- Headache
- Muscle aches
Principal Investigator
Chau Yee Ng, MD PhD
Pigment Specialist, Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan
Associate Professor, College of Medicine, Chang Gung University
Recruitment Now Open
For more information, please contact:
Study Coordinators: Min-Yi Chou, RN / Man-Ting Lin, RN
Phone: +886 922-216-828 / +886 928-577-665
Article Classification
Recent Articles
- Understanding Clinical Trials: Exploring Another Treatment Option
- Now Enrolling : Phase 2 Clinical Trial for EI-001 (Indemakitug Anti-IFN gamma antibody ) for Non-Segmental Vitiligo (NSV)
- ViPC Research & Innovation Platform in Pigmentary Medicine | Clinical Trials, Technology Validation & Translational Research